Navigation Links
Sangamo BioSciences Reports Third Quarter 2011 Financial Results
Date:10/25/2011

gher expenses for our HIV/AIDS program.  General and administrative expenses were $3.6 million for the third quarter of 2011, compared to $2.9 million for the same period in 2010. The increase was primarily due to increased professional services expenses.

Total operating expenses for the third quarter of 2011 were $11.4 million, compared to $11.7 million for the same period in 2010.  

Nine Months ResultsFor the nine months ended September 30, 2011, the consolidated net loss was $29.4 million, or $0.59 per share, compared to a consolidated net loss of $16.5 million, or $0.37 per share, for the nine months ended September 30, 2010.  Revenues were $5.6 million for the nine months of 2011, compared to $16.1 million in the same period in 2010, with the decrease primarily due to the completion, in July 2010, of the amortization period for the commercial and research license fee received from Sigma under the expanded agreement of October 2009. Total operating expenses were $35.0 million for the nine months of 2011 and $32.7 million for the same period in 2010.

Financial Guidance

  • Cash, cash equivalents and marketable securities of at least $85 million at the end of 2011, exclusive of new funding from potential future partnerships.
  • Operating expenses for 2011 to be relatively flat compared to 2010, in the range of $43 to $47 million.
  • Revenues and related cash proceeds in the range of $10 to $12 million in 2011.

  • Recent Events

  • Announcement that Sangamo's Phase 2b Trial (SB-509-901) in Subjects with Moderately Severe Diabetic Neuropathy Did Not Meet Key Endpoints. Based on the data, the Company announced that it has discontinued further development of SB-509 and will focus resources on its pipeline including ZFP Therapeutics for HIV and monogenic diseases.
  • Presentation at ICAAC 2011 of Groundbreaking Clinical Data from Sangamo's Ongoing Phase 1 Clinical Trials
    '/>"/>

  • SOURCE Sangamo BioSciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
    2. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
    3. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
    4. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
    5. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
    6. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
    7. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
    8. Sangamo Announces Pricing of Public Offering of Common Stock
    9. Sangamo Announces Public Offering of Common Stock
    10. Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntingtons Disease
    11. Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2015)... 21, 2015  Prima Biomed Ltd. (NASDAQ: PBMD ... to become a leader in the development of immunotherapeutic ... the final CVac data from the Phase II CAN-003 ... for a clinically meaningful improvement in Overall Survival ("OS") ... In the group of second remission patients ...
    (Date:5/21/2015)... , May 21, 2015 ... inner feelings - and those of others. Being able ... senses. Analyze and read people to anticipate their thoughts ... your deepest emotions and feelings to create unique abstract ... of responsive games. Get inside a first-person-shooter as it ...
    (Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
    (Date:5/21/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: ... on the development of autologous cell therapies, announced ... Society for Cellular Therapy (ISCT) on RepliCel,s autologous ... a Phase 1/2 clinical trial.  The presentation, taking ... PM to 7:00 PM local time, will review ...
    Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
    ... Dec. 13 /PRNewswire-FirstCall/ - MIGENIX Inc.,(TSX: MGI; ... for infectious,diseases, reports financial results for the ... update on its programs., UPDATE ON ... (Omigard(TM)/CPI-226/MX-226; topical cationic peptide;,prevention of catheter-related infections): ...
    ... 13 Ten new validation studies,were published during ... bringing the total number of studies published to ... considerable increase in interest from US and,European institutes" ... world,s,most highly respected academic medical institutions and teaching ...
    ... Neurocrine Biosciences,Inc. (Nasdaq: NBIX ) announced today that ... Drug Administration (FDA) indicating,that the New Drug Application (NDA) ... treatment of insomnia is approvable pending additional clinical and,preclinical ... an action letter from the FDA,stating that indiplon 5 ...
    Cached Biology Technology:MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 2MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 3MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 4MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 5MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 6MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 7MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 8MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 9MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 10MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 11MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 12MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 13MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 14MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 15MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 16MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 17MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 182007 a "Record Year" for Successful Validation Studies of Simbionix Simulators 2Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 2Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 3
    (Date:5/21/2015)... 21, 2015 According to ... Solutions (Hardware, Software, Services), by Applications (Surveillance (Airborne, ... by End-Users (Military & Defense & Commercial) - ... Imaging Market is expected to grow from $7252.0 ... at a Compound Annual Growth Rate (CAGR) of ...
    (Date:5/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... 3D-ID LLC, a company engaged in biometric identification is ... technology portion of the recently awarded TIES (Technical Information ... the Army. 3D-ID LLC has a suite ... enforcement and security agencies. Gino Pereira ...
    (Date:5/19/2015)... 19, 2015 Research ... addition of the  "Genetic Testing Market Outlook ... http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic Testing ... of the current and future genetic testing ... their working principles and types are covered ...
    Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
    ... The body is a battle zone. Cells constantly compete with ... some cells win this competition is well known to be the ... space and survival is not as clear. A study on fruit ... by Johns Hopkins researchers describes how stem cells win this battle ...
    ... CORVALLIS, Ore. According to an analysis of statewide data ... $50,000 a year were more than three times likely to ... their insurance status during pregnancy and delivery. In ... likely among mothers with Medicaid coverage, and four times more ...
    ... the Natural History Museum believe that carnivorous behaviour in plants ... grown plants such as petunias at least part ... Victorian Gothic, Darwin and modern insights into vegetable carnivory, is ... of the Linnean Society . Carnivorous plants have caught ...
    Cached Biology News:Stem cells battle for space 2Lower income women report more insurance-based discrimination during pregnancy, delivery 2Scientists think 'killer petunias' should join the ranks of carnivorous plants 2
    Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048...
    ... raised against a partial recombinant ... SLC22A3 (NP_068812, 90 a.a. ... protein with GST tag. ... NM_021977 Protein ...
    ... UniPrimer-fluorescein is a hairpin primer labeled ... (fluorescein and non-fluorescent quencher) and a ... UniPrimer is identical to the UniPrimer ... System (S7901) and is provided at ...
    ... clear polystyrene with frosted labeling surfaces, ... cell counting. 100% integrity tested. Linkage: ... product number, created to easily match ... availability yet, please order under the ...
    Biology Products: